

Patient/carer organisation statement template

Bendamustine for the initial treatment of CLL

About you

Your name: [REDACTED]

Name of your organisation: Leukaemia CARE

Are you (tick all that apply):

- an employee of a patient organisation that represents patients with the condition for which NICE is considering the technology?

See above for name and role.

Appendix I – Patient/carer organisation statement template

I have had sight of the submission on Bendamustine for the initial treatment of CLL that was prepared and returned to NICE by the Lymphoma Association. It is an accurate and very comprehensive review of the patients' perspective of CLL and its treatment; and rather than replicate the work that they have very effectively already completed I fully endorse their submission on behalf of Leukaemia CARE.

I trust that this is satisfactory

Kind regards

██████████